INTEL 264

To provide a comprehensive estimate of the potential income stream from legalizing and monopolizing drug markets across Western and Central Europe (including the EU), we need to incorporate consumption and spending data for these regions. Here’s a step-by-step approach to estimate the additional revenue from these regions and combine it with the previous estimates for North America.

1. Estimated Annual Spending on Each Substance in Western and Central Europe

Spending Estimates:

1. Cocaine:

• Western Europe: Approximately $30 billion annually.
• Central Europe: Approximately $10 billion annually.
• Total: ~$40 billion

1. Amphetamines (including methamphetamine):

• Western Europe: Approximately $15 billion annually.
• Central Europe: Approximately $5 billion annually.
• Total: ~$20 billion

1. Oxycodone and Prescription Painkillers:

• Western Europe: Approximately $10 billion annually.
• Central Europe: Approximately $3 billion annually.
• Total: ~$13 billion

1. Cannabis (Weed):

• Western Europe: Approximately $10 billion annually.
• Central Europe: Approximately $3 billion annually.
• Total: ~$13 billion

1. Psychedelics (Shrooms, LSD):

• Western Europe: Approximately $2 billion annually.
• Central Europe: Approximately $500 million annually.
• Total: ~$2.5 billion

1. Ecstasy (MDMA):

• Western Europe: Approximately $5 billion annually.
• Central Europe: Approximately $1 billion annually.
• Total: ~$6 billion

1. Viagra and Similar Drugs:

• Western Europe: Approximately $2 billion annually.
• Central Europe: Approximately $500 million annually.
• Total: ~$2.5 billion

2. Aggregating the Revenue Potential

Tax Revenue (25% of Spending):

• Cocaine: $40 billion x 25% = $10 billion
• Amphetamines: $20 billion x 25% = $5 billion
• Oxycodone and Painkillers: $13 billion x 25% = $3.25 billion
• Cannabis: $13 billion x 25% = $3.25 billion
• Psychedelics: $2.5 billion x 25% = $625 million
• Ecstasy: $6 billion x 25% = $1.5 billion
• Viagra: $2.5 billion x 25% = $625 million Subtotal from Taxes: $24.25 billion

Regulatory Fees (10% of Spending):

• Cocaine: $40 billion x 10% = $4 billion
• Amphetamines: $20 billion x 10% = $2 billion
• Oxycodone and Painkillers: $13 billion x 10% = $1.3 billion
• Cannabis: $13 billion x 10% = $1.3 billion
• Psychedelics: $2.5 billion x 10% = $250 million
• Ecstasy: $6 billion x 10% = $600 million
• Viagra: $2.5 billion x 10% = $250 million Subtotal from Regulatory Fees: $10.7 billion

Reduced Law Enforcement Costs (20% of Spending):

• Cocaine: $40 billion x 20% = $8 billion
• Amphetamines: $20 billion x 20% = $4 billion
• Oxycodone and Painkillers: $13 billion x 20% = $2.6 billion
• Cannabis: $13 billion x 20% = $2.6 billion
• Psychedelics: $2.5 billion x 20% = $500 million
• Ecstasy: $6 billion x 20% = $1.2 billion
• Viagra: Not applicable Subtotal from Reduced Law Enforcement Costs: $19.9 billion

3. Total Estimated Income Stream for Western and Central Europe

Combining the revenue streams:

• Tax Revenue: $24.25 billion
• Regulatory Fees: $10.7 billion
• Reduced Law Enforcement Costs: $19.9 billion

Total Estimated Income Stream for Western and Central Europe: $54.85 billion annually

4. Combining with North America

From the previous estimate for North America:

• Total Estimated Income Stream (North America): $146.875 billion

Adding the European figures:

Total Estimated Income Stream (North America + Western and Central Europe): $146.875 billion + $54.85 billion = $201.725 billion annually

5. Conclusion

The total potential income stream from legalizing and monopolizing these drug markets across North America and Western and Central Europe could be around $201.725 billion annually. This estimate includes revenue from taxes, regulatory fees, and reduced law enforcement costs. As with any such model, actual revenue could vary based on market dynamics, regulatory effectiveness, and societal impacts.